Clinical trials
Observational Crohn Disease trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
61 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 10 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 8 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Recruiting | 14 |
| Unknown status | 14 |
| Active, not recruiting | 2 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Second Affiliated Hospital of Wenzhou Medical University | 13 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 10 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 9 |
| Shanghai 10th People's Hospital | 6 |
| AbbVie | 3 |
| Jinling Hospital, China | 2 |
| Takeda | 2 |
| The Third Xiangya Hospital of Central South University | 2 |
| Xiang Gao | 2 |
| Chen QiYi | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Crohn Disease | 61 |
| Inflammatory Bowel Diseases | 14 |
| Colitis, Ulcerative | 13 |
| Constriction, Pathologic | 2 |
| Fibrosis | 2 |
| Abdominal Abscess | 1 |
| Autism Spectrum Disorder | 1 |
| Congenital Microtia | 1 |
| Digestive System Diseases | 1 |
| Disease Progression | 1 |
Trials
Showing 1 to 25 of 61. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.